Human-induced pluripotent stem cells (hiPSCs) give researchers in pharmaceutical and biotechnology organizations access to human cell types that otherwise are hard to obtain or work with. However, hiPSCs can only be an effective model when they accurately and consistently represent human biology. This challenge may be a contributing factor in the high failure rate of therapeutics. Fortunately, new techniques have been developed, creating more consistent and well-defined hiPSC-derived cells like ioMicroglia from bit.bio.
Download this case study from bit.bio to learn how a leading CRO used ioMicroglia cells to build better and more reliable in vitro assays for evaluating the therapeutic potential of microglia-targeted compounds.
